ImmuneOnco won "Drug Innovation Award" by Securities Times-宜明昂科英文

Home Company News News detail

ImmuneOnco won "Drug Innovation Award" by Securities Times

2022-08-06

409

On August 6, 2022, the Securities Times Biomedical Innovation Forum and the 2nd Drug Innovation Award Ceremony hosted by the Securities Times were held in Shanghai. Chairman founder of ImmuneOnco，Dr.Tian, Wenzhi,, was successfully selected as the "Top Ten Drug Innovation Scientists in 2021", and Drug candidate IMM2902 for Injection won the "Annual Drug Innovation Pioneering Award".

Previous article：IMM40H was approved almost simultaneously by China NMPA and US FDA for clinical trial research

Next article：ImmuneOnco started Phase Ib/II Clinical Study of IMM01: An IMM01 combined with azacitidine clinical trial completed the first patient enrollment and dosing

Back

Hot recommendation

2025-01-13

ImmuneOnco IMM2510 Combined with Chemotherapy for First-Line NSCLC Treatment Completes Enrollment of First Patient in Phase Ib/II Clinical Trial

2024-11-13

The Phase II clinical trial of IMM27M for estrogen receptor positive (ER+) advanced breast cancer that failed after endocrine therapy or recurred and has enrolled the first patient

2024-09-16

ImmuneOnco and Instil Bio Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, IMM2510/SYN-2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

For more information

Please follow the official wechat public account